ID   KY821
AC   CVCL_1346
SY   KY-821
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03470792
DR   CCLE; KY821_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM00553
DR   ChEMBL-Cells; CHEMBL3308834
DR   ChEMBL-Targets; CHEMBL2366190
DR   Cosmic; 907300
DR   Cosmic; 975264
DR   Cosmic; 2089651
DR   Cosmic; 2131567
DR   Cosmic-CLP; 907300
DR   DepMap; ACH-002262
DR   GDSC; 907300
DR   GEO; GSM827265
DR   GEO; GSM1670013
DR   IARC_TP53; 2196
DR   IARC_TP53; 21447
DR   JCRB; JCRB0105
DR   LINCS_LDP; LCL-1004
DR   PharmacoDB; KY821_797_2019
DR   Progenetix; CVCL_1346
DR   Wikidata; Q54900774
RX   CelloPub=CLPUB00069;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1560671;
RX   PubMed=1571549;
RX   PubMed=8387619;
RX   PubMed=9747033;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21552520;
RX   PubMed=23955599;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: ~2 days (lot 11022006) (JCRB).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=1571549; CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=76.02%; East Asian, South=23.98%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from sampling site: Brain; meninges.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9,12
ST   D16S539: 10,12
ST   D5S818: 10,13
ST   D7S820: 12
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C7463; Acute myelomonocytic leukemia
DI   ORDO; Orphanet_517; Acute myelomonocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   28Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 30
//
RX   CelloPub=CLPUB00069;
RA   Kishi K., Hanano M., Hirosawa H., Koike T., Sakai C., Aoyagi Y.,
RA   Sanada M., Moiyama Y., Shibata A.;
RT   "Characterization of a new human granulo-monocytic leukemic cell
RT   line.";
RL   Acta Haematol. Jpn. 46:122-122(1983).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1560671; DOI=10.1016/0145-2126(92)90059-G;
RA   Saito H., Kishi K., Narita M., Furukawa T., Nagura E., Maekawa T.,
RA   Abe T., Shibata A.;
RT   "A new myeloblastic leukemia cell line with double minute chromosomes.
RT   Induction of methotrexate resistance and dihydrofolate reductase gene
RT   amplification.";
RL   Leuk. Res. 16:217-226(1992).
//
RX   PubMed=1571549; DOI=10.1182/blood.V79.9.2378.2378;
RA   Sugimoto K., Toyoshima H., Sakai R., Miyagawa K., Hagiwara K.,
RA   Ishikawa F., Takaku F., Yazaki Y., Hirai H.;
RT   "Frequent mutations in the p53 gene in human myeloid leukemia cell
RT   lines.";
RL   Blood 79:2378-2383(1992).
//
RX   PubMed=8387619; DOI=10.1016/0145-2126(93)90019-H;
RA   Fukuda T., Kakihara T., Kamishima T., Ohnishi Y., Naito M., Kishi K.,
RA   Shibata A.;
RT   "Different effects of various hematopoietic growth factors on
RT   myelomonocytic cell line (KY-821) and its drug-resistant sublines.";
RL   Leuk. Res. 17:325-332(1993).
//
RX   PubMed=9747033; DOI=10.1007/s100380050067;
RA   Ariyama Y., Sakabe T., Shinomiya T., Mori T., Fukuda Y., Inazawa J.;
RT   "Identification of amplified DNA sequences on double minute
RT   chromosomes in a leukemic cell line KY821 by means of spectral
RT   karyotyping and comparative genomic hybridization.";
RL   J. Hum. Genet. 43:187-190(1998).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21552520; DOI=10.1371/journal.pone.0019169;
RA   Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A.,
RA   Tucker M., Kornhauser J., Ren J., MacNeill J., Gygi S.P., Druker B.J.,
RA   Heinrich M.C., Rush J., Polakiewicz R.D.;
RT   "Survey of activated FLT3 signaling in leukemia.";
RL   PLoS ONE 6:E19169-E19169(2011).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//